

DEPARTMENT OF JUSTICE

Notice of Lodging of Consent Decree Pursuant to the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as Amended

Notice is hereby given that a proposed consent decree in the action entitled *United States v. Holden, et al.*, Civil Action No. 00CV11036EFH (D. Mass.), was lodged on May 26, 2000, with the United States District Court for the District of Massachusetts. The proposed consent decree resolves the claims of the United States against several potentially responsible parties ("Settling Defendants") at the Nyanza Chemical Waste Dump Superfund Site, located in Ashland, Massachusetts ("Site"), under the Comprehensive Environmental Response, Compensation, and Liability Act ("CERCLA"), 42 U.S.C. 9601 *et seq.* The consent decree will also resolve the claims of the Commonwealth of Massachusetts ("Commonwealth") in connection with the Site under CERCLA and the Massachusetts Oil and Hazardous Material Release Prevention and Response Act, M.G.L. c. 21E. The Settling Defendants include Nelson W. Holden, as Trustee of the Holden-Ashland Trust, Martha E. Holden, as Trustee of the Holden-Ashland Trust, and William M. Leacu. The Environmental Protection Agency has determined that the Settling Defendants qualify for a *de minimis* settlement under section 122(g)(1)(B) of CERCLA, 42 U.S.C. 9622(g)(1)(B). The consent decree includes a covenant not to sue by the United States under sections 106 and 107 of CERCLA, 42 U.S.C. 9606 and 9607 (including claims for natural resources damages), and under Section 7003 of the Resource Conservation and Recovery Act ("RCRA"), 42 U.S.C. 6973.

Under the proposed consent decree, the Settling Defendants have agreed to record an Environmental Restriction and Easement ("Easement") with respect to each of their properties located at the Site. The Easements will impose certain restrictions on the use of these properties and will also provide access rights to the United States (until completion of the remedial action at the Site) and to the Commonwealth (after completion of the remedial action at the Site).

The Department of Justice will receive, for a period of up to thirty days from the date of this publication, comments relating to the proposed consent decree. Any comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, P.O. box

7611, Ben Franklin Station, Washington DC 20044, and should refer to *United States v. Holden, et al.*, DOJ Ref. Number 90-11-2-340C. Commenters may request an opportunity for a public meeting in the affected area, in accordance with Section 7003(d) of RCRA, 42 U.S.C. 6973(d).

The proposed consent decree may be examined at EPA Region 1, located at One Congress Street, Suite 1100, Boston, MA 02114 (contact Peter DeCambre, 617-918-1890). A copy of the proposed consent decree may be obtained by mail from the Department of Justice Consent Decree Library, P.O. Box 7611, Washington, DC 20044. In requesting a copy, please refer to the referenced case and enclose a check in the amount of \$23.75 (25 cents per page reproduction costs).

Joel M. Gross,

Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 00-14456 Filed 6-7-00; 8:45 am]

BILLING CODE 4410-15-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration**Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated February 10, 2000, and published in the **Federal Register** on February 17, 2000, (65 FR 33) Ganes Chemicals Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Methylphenidate (1724)	II
Amobarbital (2125)	II
Pentobarbital (2270)	II
Secobarbital (2315)	II
Glutethimide (2550)	II
Methadone (9250)	II
Methadone-intermediate (9254)	II
Dextropoxyphene, bulk (non-dosage forms) (9273)	II

The firm plans to manufacture the listed controlled substances for distribution as bulk products to its customers.

DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Ganes Chemicals, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has

investigated Ganes Chemicals, Inc. on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: May 25, 2000.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 00-14478 Filed 6-7-00; 8:45 am]

BILLING CODE 4410-09-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration**Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated May 12, 1999, and published in the **Federal Register** on May 25, 1999, (64 FR 28214), Noramco, Inc., 1400 Olympic Drive, Athens, Georgia 30601, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Codeine (9050)	II
Oxycodone (9143)	II
Hydrocodone (9193)	II
Morphine (9300)	II
Thebaine (9333)	II

The firm plans to support its other manufacturing facility with manufacturing and analytical testing.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Noramco, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Noramco, Inc. to ensure that the company's registration is consistent with the public interest. The investigations included inspection and testing of the company's physical